What is the first-line treatment for a typical adult with major depressive disorder?

First-Line Treatment for Depression

For adults with moderate to severe major depressive disorder, initiate either a second-generation antidepressant (SSRI or SNRI) or cognitive-behavioral therapy (CBT), as both achieve equivalent remission rates of 46–54% with a number needed to treat of 7–8. 1, 2

Treatment Selection Algorithm

Step 1: Confirm Diagnosis and Severity

• Verify ≥5 symptoms present for ≥2 weeks including depressed mood or anhedonia, plus functional impairment in work, home, or social domains 3
• Use PHQ-9, HAM-D, or MADRS to quantify baseline severity 3
• Screen immediately for suicidal ideation, plan, intent, prior attempts, psychotic features, substance use disorders, and comorbid anxiety 3

Step 2: Choose Between Pharmacotherapy and Psychotherapy

For moderate to severe depression (≥7 symptoms):

• Either an SSRI/SNRI or CBT is appropriate first-line monotherapy 1, 2
• Choose pharmacotherapy when: rapid symptom relief is needed, trained CBT therapists are unavailable, or patient prefers medication 2
• Choose CBT when: patient wishes to avoid medication side effects, concerns about sexual dysfunction or weight gain exist, or lower relapse rates after discontinuation are prioritized 2

For severe depression (≥9 symptoms, severe functional impairment, or high-risk features):

• Initiate combination therapy with both an SSRI/SNRI and CBT concurrently, as this nearly doubles remission rates (57% vs 31% with medication alone) 1, 3

Step 3: Select Specific SSRI/SNRI

General adult population (ages 25–64):

• Sertraline, escitalopram, citalopram, or fluoxetine are appropriate first choices 1, 4
• All SSRIs have equivalent efficacy; selection should prioritize adverse-effect profile, cost, and dosing convenience 1, 2

Older adults (≥65 years):

• Preferred agents: citalopram, sertraline, venlafaxine, or bupropion 1, 2
• Avoid paroxetine and fluoxetine due to higher anticholinergic effects 1, 2

Specific clinical scenarios:

• Cognitive symptoms (difficulty concentrating, mental fog): Bupropion is first choice, SNRIs second choice 1, 2
• Comorbid chronic pain: SNRIs (duloxetine or venlafaxine) achieve higher remission rates (49% vs 42% for SSRIs) 1, 2
• Sexual dysfunction concerns: Bupropion has the lowest rate of sexual adverse effects 1, 2
• Breastfeeding mothers: Sertraline or paroxetine achieve lower breast milk concentrations 1
• Comorbid panic disorder: Sertraline, fluoxetine, or paroxetine hold dual FDA approval 3, 4

Step 4: Dosing and Initiation

• Escitalopram: Start 10 mg once daily 3
• Sertraline, fluoxetine, paroxetine, citalopram: Start 20 mg once daily 3
• Use "start low, go slow" approach in older adults 1

Safety Monitoring Protocol

Week 1–2 (mandatory early assessment):

• Evaluate for suicidal thoughts, plans, behaviors, agitation, irritability, or atypical behavioral changes 1, 2, 3
• Suicide risk peaks during the first 1–2 months of SSRI treatment 1, 3
• Age-specific suicide risk with SSRIs:
  • Ages 18–24: increased risk (OR 2.30) 1, 2
  • Ages 25–64: neutral effect 1, 2
  • Ages ≥65: protective effect (OR 0.06) 1, 2

Weeks 6–8 (response assessment):

• If symptom reduction is <50% on validated scales, modify treatment by dose escalation, switching to different antidepressant class, augmentation with bupropion or buspirone, or adding CBT 1, 2, 3
• Do not switch from one SSRI to another SSRI, as this produces no significant difference in response rates; switch to a different class instead 1

Treatment Duration

First depressive episode:

• Continue therapy for 4–9 months after achieving remission to prevent relapse 1, 2, 3

Recurrent depression (≥2 prior episodes):

• Maintain treatment for ≥12 months or longer 1, 2, 3

Common Adverse Effects

• Approximately 63% of patients experience at least one adverse effect 1, 2
• Most common: nausea/vomiting (leading cause of discontinuation), diarrhea, dizziness, dry mouth, fatigue, headache, sexual dysfunction 1
• Paroxetine has notably higher rates of sexual dysfunction and anticholinergic effects than other SSRIs 1, 2

Critical Pitfalls to Avoid

• Never use tricyclic antidepressants as first-line agents due to higher adverse-effect burden, overdose risk, and no superiority over SSRIs/SNRIs 1, 2, 3
• Do not prescribe antidepressants for mild depression or subsyndromal symptoms without a current moderate-to-severe episode 1, 2
• Do not discontinue treatment prematurely; minimum 4–9 months continuation is required 1, 2, 3
• Do not assume all SSRIs are identical; paroxetine carries higher anticholinergic and sexual dysfunction risks 1, 2